Lung cancer deaths leveling off for EU women, except in Spain
“Now, in a new study published in the leading cancer journal Annals of Oncology today (Monday), researchers led by Carlo La Vecchia (MD), Professor of Medical Statistics and Epidemiology at the University of Milan (Italy), predict that age standardized death rates (ASR) from lung cancer among EU women will stabilize at around 12.5 deaths per 100,000 women in 2026. This represents a fall of just over 5% since 2020-2022. The only exception is Spain, where female lung cancer death rates will continue to rise by 2.4% in 2026, with around 10 deaths per 100,000 women.”
Epigenetic Drug Switches Off Tumor-Driving Genes in Lung Cancer
“A research team led by Professor Xiang David Li from the Department of Chemistry at The University of Hong Kong (HKU), in collaboration with researchers from the Shenzhen Bay Laboratory and Tsinghua University, has made a breakthrough in epigenetic drug discovery. The team has successfully developed a first-in-class chemical inhibitor that precisely and selectively targets the ATAC complex, a critical cellular “switch operator” that activates tumour-promoting genes, opening a novel therapeutic avenue for non-small cell lung cancer (NSCLC).”
Rates of lung cancer decrease with screenings
“MIDLAND, Texas (KMID/KPEJ)- The Texas Medical Association reported fewer cases of lung cancer across Texas in 2025. “What we’ve seen is that we’ve been able to capture in our high-risk patients lung cancers at an earlier stage, that’s more treatable rather than at a later stage, so an early stage if we’re able to catch it then the survival rate can be anywhere from 75 to 90%, even over 90% of the patients can survive,” pulmonologist Dr. Neel Bhan said.”
Dana-Farber Study Finds Dual Immunotherapy May Help Certain Patients with Advanced Non-Small Cell Lung Cancer Live Longer
“Summary: A global analysis led by Dana-Farber researchers combined detailed patient data from six major clinical trials to compare two types of immunotherapies for advanced non-small cell lung cancer (NSCLC): dual immunotherapy (a combination of CTLA-4 and PD-1/PD-L1 inhibitors) and single immunotherapy (PD-1/PD-L1 inhibitors alone).”
Bristol Myers Squibb taps Microsoft’s AI detection network for speedy lung cancer diagnosis
“The U.S. tech giant will provide its suite of artificial-intelligence-powered radiology tools to BMS to help detect non-small cell lung cancer (NSCLC) more quickly across U.S. hospitals using Microsoft’s Precision Imaging Network. More than 80% of hospitals in the U.S. use Microsoft’s network, which is designed to share medical imaging and access third-party imaging AI, the tech company said in a Jan. 20 release.”
Researchers announce notable breakthrough in cancer outcomes
“ATLANTA, Georgia — The American Cancer Society marked a historic moment Tuesday, reporting that the five-year survival rate for all cancers combined has reached 70% for the first time, a milestone driven largely by major gains in treating some of the deadliest forms of the disease.”
Penpulimab Regimens Show Promise in Resectable NSCLC Trial
“Perioperative penpulimab-kcqx plus anlotinib with or without neoadjuvant chemotherapy demonstrated promising efficacy and a manageable safety profile among patients with resectable non–small cell lung cancer (NSCLC), according to data from the phase 2 ALTER-L043 trial (NCT04846634) published in Signal Transduction and Targeted Therapy.”
FDA Clears LEADOPTIK’s LIA System for Higher-Accuracy Lung Biopsy
“Key Takeaways: LEADOPTIK’s LIA system integrates high-resolution depth imaging into biopsy tools, improving lung biopsy accuracy and addressing current workflow limitations. The LIA system offers 50x better imaging resolution than existing technologies, enhancing confidence in biopsy procedures.”
LUNGevity and Rising Tide Foundation Issue RFA Tackling Lung Cancer’s Toughest Challenges: Drug Resistance and Cancer Recurrence
“WASHINGTON, Jan. 15, 2026 /PRNewswire/ — LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, and Rising Tide Foundation for Clinical Cancer Research (RTFCCR) announced a joint call for research proposals aimed at tackling two of the most urgent challenges in lung cancer care: early detection of disease recurrence and overcoming treatment resistance.”
Americans Know Little about the Leading Cause of Cancer Death
“WASHINGTON, Jan. 13, 2026 /PRNewswire/ — Lung cancer kills more Americans each year than any other cancer — yet most Americans are uninformed about this disease. A new national survey commissioned by the Lung Cancer Action Network (LungCAN) shows that after seven years of expanded screening guidelines and major scientific advances, public understanding of lung cancer has not meaningfully improved.”
